Cargando…
Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract
Objective: To evaluate the clinical outcomes of UTUC patients with or without concurrent bladder tumor. Design, Setting, and Participants: The Clinical Research Office of the Endourology Society-Urothelial Carcinomas of the Upper Tract (CROES-UTUC) Registry included 1134 UTUC patients with or withou...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776685/ https://www.ncbi.nlm.nih.gov/pubmed/36547141 http://dx.doi.org/10.3390/curroncol29120727 |
_version_ | 1784855922865078272 |
---|---|
author | Liu, Kang Zhao, Hongda Alvarez-Maestro, Mario Gravas, Stavros Van Renterghem, Koen Zeng, Guohua Ng, Chi-Fai Laguna, Pilar Teoh, Jeremy Yuen-Chun De La Rosette, Jean |
author_facet | Liu, Kang Zhao, Hongda Alvarez-Maestro, Mario Gravas, Stavros Van Renterghem, Koen Zeng, Guohua Ng, Chi-Fai Laguna, Pilar Teoh, Jeremy Yuen-Chun De La Rosette, Jean |
author_sort | Liu, Kang |
collection | PubMed |
description | Objective: To evaluate the clinical outcomes of UTUC patients with or without concurrent bladder tumor. Design, Setting, and Participants: The Clinical Research Office of the Endourology Society-Urothelial Carcinomas of the Upper Tract (CROES-UTUC) Registry included 1134 UTUC patients with or without concurrent bladder tumor treated between 2014 and 2019. Results: In 218 (19.2%) cases, concurrent bladder tumor was present, while in 916 (80.8%) patients, no bladder cancer was found. In the multivariable Cox regression analysis, concomitant bladder tumor (hazard ratio (HR) 1.562, 95% confidence interval (CI) 0.954–2.560, p = 0.076) indicated a trend associated with recurrence-free survival for UTUC. Further data dissection confirmed that concomitant bladder tumor is a risk factor of bladder recurrence (HR 1.874, 95% CI 1.104–3.183, p = 0.020) but not UTUC recurrence (HR 0.876, 95% CI 0.292–2.625, p = 0.812). Kidney-sparing surgery (KSS) (HR 3.940, 95% CI 1.352–11.486, p = 0.012), pathological T staging ≥ pT2 (HR 2.840, 95% 1.039–7.763, p = 0.042) were significantly associated with UTUC recurrence. KSS does not affect bladder recurrence (HR 0.619, 95% CI 0.242–1.580, p = 0.315). A limitation is the retrospective nature of the present study analysis. Conclusions: The presence of concomitant bladder tumor does not increase risk of UTUC recurrence, but it results in an increased risk of bladder recurrence. KSS does not affect bladder recurrence and can still be considered in patients with concomitant bladder tumor. |
format | Online Article Text |
id | pubmed-9776685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97766852022-12-23 Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract Liu, Kang Zhao, Hongda Alvarez-Maestro, Mario Gravas, Stavros Van Renterghem, Koen Zeng, Guohua Ng, Chi-Fai Laguna, Pilar Teoh, Jeremy Yuen-Chun De La Rosette, Jean Curr Oncol Article Objective: To evaluate the clinical outcomes of UTUC patients with or without concurrent bladder tumor. Design, Setting, and Participants: The Clinical Research Office of the Endourology Society-Urothelial Carcinomas of the Upper Tract (CROES-UTUC) Registry included 1134 UTUC patients with or without concurrent bladder tumor treated between 2014 and 2019. Results: In 218 (19.2%) cases, concurrent bladder tumor was present, while in 916 (80.8%) patients, no bladder cancer was found. In the multivariable Cox regression analysis, concomitant bladder tumor (hazard ratio (HR) 1.562, 95% confidence interval (CI) 0.954–2.560, p = 0.076) indicated a trend associated with recurrence-free survival for UTUC. Further data dissection confirmed that concomitant bladder tumor is a risk factor of bladder recurrence (HR 1.874, 95% CI 1.104–3.183, p = 0.020) but not UTUC recurrence (HR 0.876, 95% CI 0.292–2.625, p = 0.812). Kidney-sparing surgery (KSS) (HR 3.940, 95% CI 1.352–11.486, p = 0.012), pathological T staging ≥ pT2 (HR 2.840, 95% 1.039–7.763, p = 0.042) were significantly associated with UTUC recurrence. KSS does not affect bladder recurrence (HR 0.619, 95% CI 0.242–1.580, p = 0.315). A limitation is the retrospective nature of the present study analysis. Conclusions: The presence of concomitant bladder tumor does not increase risk of UTUC recurrence, but it results in an increased risk of bladder recurrence. KSS does not affect bladder recurrence and can still be considered in patients with concomitant bladder tumor. MDPI 2022-11-28 /pmc/articles/PMC9776685/ /pubmed/36547141 http://dx.doi.org/10.3390/curroncol29120727 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liu, Kang Zhao, Hongda Alvarez-Maestro, Mario Gravas, Stavros Van Renterghem, Koen Zeng, Guohua Ng, Chi-Fai Laguna, Pilar Teoh, Jeremy Yuen-Chun De La Rosette, Jean Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract |
title | Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract |
title_full | Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract |
title_fullStr | Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract |
title_full_unstemmed | Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract |
title_short | Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract |
title_sort | concomitant bladder tumor is a risk factor for bladder recurrence but not upper tract |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776685/ https://www.ncbi.nlm.nih.gov/pubmed/36547141 http://dx.doi.org/10.3390/curroncol29120727 |
work_keys_str_mv | AT liukang concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT zhaohongda concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT alvarezmaestromario concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT gravasstavros concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT vanrenterghemkoen concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT zengguohua concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT ngchifai concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT lagunapilar concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT teohjeremyyuenchun concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract AT delarosettejean concomitantbladdertumorisariskfactorforbladderrecurrencebutnotuppertract |